[Clinical study of weekly administration of @entity1311 for advanced and metastatic XXXX ].

@entity1 @entity1665 @entity1087 @entity5 @entity843 @entity1311 @entity1897 @entity1431 @entity158 @entity356
Ten cases of advanced and metastatic @entity356 treated by weekly administration of @entity1311 were studied. The @entity1 were 50-72 years of age, including 9 @entity1 and 1 @entity1 . In this study, @entity1311 was administered by 1 hour intravenous infusion at a dose of 50-80 mg/m2 every week. Administration was continued for 3 weeks with 1 week rest. One to four cycles were performed at minimum. @entity1311 was administered in 5 cases as 1st line treatment, 4 cases as 2nd line treatment and 1 case as 3rd line treatment. There were 2 partial responders and no complete responders, and the overall response rate was 20%. The response rate was 100% in liver, 100% in lung, 16% in lymphnodes, and 0% in peritonial dissemination. The clinical symptoms of @entity158 and @entity1087 abated in one case, the size of the @entity5 decreased in one case, and a @entity843 was seen in two cases. The level of @entity5 marker was decreased in 3 out of 10 cases. Side effects included grade 3/4 @entity1431 in 10% of @entity1 , and @entity1665 in 50%, but @entity1897 was not observed. Weekly administration of @entity1311 appears to be well-tolerated and effective against advanced and metastatic @entity356 .
